Monophosphate Lipid A's TRIF-biased TLR4 signaling results in weak NLRP3 inflammasome priming and reduced IL1beta production, leading to decreased inflammation in vivo compared to Lipid A. (136.38)

Chelsea Eaves,Luigi Franchi,Eron Roy,Gabriel Nunez,Thomas Mitchell

DOI: https://doi.org/10.4049/jimmunol.184.supp.136.38

2010-04-01

The Journal of Immunology

Abstract:Abstract Monophosphate Lipid A (MLA), a PAMP variant of the Lipid A moiety from LPS, exhibits 100-fold reduced toxicity than its parent molecule. We previously characterized MLA as TRIF-biased agonists of TLR4, meaning that while inductions of TRIF-dependent transcripts are comparable to Lipid A, MyD88-dependent transcripts are greatly reduced. Previous studies showed that MLA fails to induce IL1beta production from monocytic cell culture, and it was suggested that the lack of production of this pro-inflammatory cytokine could be responsible for MLA’s reduced toxicity. Our initial goal was to reconcile TRIF-biased TLR4 signaling and IL1beta loss with MLA’s reduced induction of inflammatory mediators. We find that MLA’s TRIF-biased TLR4 signaling leads to weak NLRP3 inflammasome priming and reduced IL1beta production from murine bone marrow derived dendritic cells. Comparison of inflammatory transcripts from spleen and liver of MLA and Lipid A treated WT or IL1RImutant mice suggests that IL1beta plays a critical role in the toxicity of Lipid A in vivo. We propose that TRIF-biased TLR4 signaling by MLA results in weak inflammasome priming, reduced IL1beta production and decreased induction of inflammatory mediators in vivo.

immunology